These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36055227)

  • 1. Cellular hierarchies predict drug response in acute myeloid leukemia.
    Raffel S; Velten L; Haas S
    Cancer Cell; 2022 Sep; 40(9):917-919. PubMed ID: 36055227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.
    Bottomly D; Long N; Schultz AR; Kurtz SE; Tognon CE; Johnson K; Abel M; Agarwal A; Avaylon S; Benton E; Blucher A; Borate U; Braun TP; Brown J; Bryant J; Burke R; Carlos A; Chang BH; Cho HJ; Christy S; Coblentz C; Cohen AM; d'Almeida A; Cook R; Danilov A; Dao KT; Degnin M; Dibb J; Eide CA; English I; Hagler S; Harrelson H; Henson R; Ho H; Joshi SK; Junio B; Kaempf A; Kosaka Y; Laderas T; Lawhead M; Lee H; Leonard JT; Lin C; Lind EF; Liu SQ; Lo P; Loriaux MM; Luty S; Maxson JE; Macey T; Martinez J; Minnier J; Monteblanco A; Mori M; Morrow Q; Nelson D; Ramsdill J; Rofelty A; Rogers A; Romine KA; Ryabinin P; Saultz JN; Sampson DA; Savage SL; Schuff R; Searles R; Smith RL; Spurgeon SE; Sweeney T; Swords RT; Thapa A; Thiel-Klare K; Traer E; Wagner J; Wilmot B; Wolf J; Wu G; Yates A; Zhang H; Cogle CR; Collins RH; Deininger MW; Hourigan CS; Jordan CT; Lin TL; Martinez ME; Pallapati RR; Pollyea DA; Pomicter AD; Watts JM; Weir SJ; Druker BJ; McWeeney SK; Tyner JW
    Cancer Cell; 2022 Aug; 40(8):850-864.e9. PubMed ID: 35868306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.
    Zeng AGX; Bansal S; Jin L; Mitchell A; Chen WC; Abbas HA; Chan-Seng-Yue M; Voisin V; van Galen P; Tierens A; Cheok M; Preudhomme C; Dombret H; Daver N; Futreal PA; Minden MD; Kennedy JA; Wang JCY; Dick JE
    Nat Med; 2022 Jun; 28(6):1212-1223. PubMed ID: 35618837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
    Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
    Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemia stem cells in acute myeloid leukemia.
    Chan WI; Huntly BJ
    Semin Oncol; 2008 Aug; 35(4):326-35. PubMed ID: 18692683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
    Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
    Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
    Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
    Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
    Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA
    JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A precision medicine classification for treatment of acute myeloid leukemia in older patients.
    Mims AS; Kohlschmidt J; Borate U; Blachly JS; Orwick S; Eisfeld AK; Papaioannou D; Nicolet D; Mrόzek K; Stein E; Bhatnagar B; Stone RM; Kolitz JE; Wang ES; Powell BL; Burd A; Levine RL; Druker BJ; Bloomfield CD; Byrd JC
    J Hematol Oncol; 2021 Jun; 14(1):96. PubMed ID: 34162404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Abnormalities in Acute Myeloid Leukemia and Leukemia Stem Cells.
    Xu J; Hang X; Wu B; Chen C; Liu Y
    Adv Exp Med Biol; 2019; 1143():173-189. PubMed ID: 31338820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism.
    Saxena K; Konopleva M
    Expert Opin Investig Drugs; 2020 Sep; 29(9):973-988. PubMed ID: 32746655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD123-targeted therapy in acute myeloid leukemia.
    Espinoza-Gutarra MR; Green SD; Zeidner JF; Konig H
    Expert Rev Hematol; 2021 Jun; 14(6):561-576. PubMed ID: 34043467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations.
    Salci KR; Lee JH; Laronde S; Dingwall S; Kushwah R; Fiebig-Comyn A; Leber B; Foley R; Dal Cin A; Bhatia M
    Stem Cells; 2015 Jun; 33(6):1839-49. PubMed ID: 25764124
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Nguyen CH; Grandits AM; Purton LE; Sill H; Wieser R
    Cell Cycle; 2020 Oct; 19(20):2573-2588. PubMed ID: 32900260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.
    Pollyea DA; Gutman JA; Gore L; Smith CA; Jordan CT
    Haematologica; 2014 Aug; 99(8):1277-84. PubMed ID: 25082785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-cell survey of cellular hierarchy in acute myeloid leukemia.
    Wu J; Xiao Y; Sun J; Sun H; Chen H; Zhu Y; Fu H; Yu C; E W; Lai S; Ma L; Li J; Fei L; Jiang M; Wang J; Ye F; Wang R; Zhou Z; Zhang G; Zhang T; Ding Q; Wang Z; Hao S; Liu L; Zheng W; He J; Huang W; Wang Y; Xie J; Li T; Cheng T; Han X; Huang H; Guo G
    J Hematol Oncol; 2020 Sep; 13(1):128. PubMed ID: 32977829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
    Laing AA; Harrison CJ; Gibson BES; Keeshan K
    Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.